Patent application number | Description | Published |
20090292917 | SECURE TRANSPORT OF MULTICAST TRAFFIC - Secure tunneled multicast transmission and reception through a network is provided. A join request may be received from a second tunnel endpoint, the join request indicating a multicast group to be joined. Group keys may be transmitted to the second tunnel endpoint, where the group keys are based at least on the multicast group. A packet received at the first tunnel endpoint may be cryptographically processed to generate an encapsulated payload. A header may be appended to the encapsulated payload to form an encapsulated packet, wherein the header includes information associated with the second tunnel endpoint. A tunnel may be established between the first tunnel endpoint and the second tunnel endpoint based on the appended header. The encapsulated packet may be transmitted through the tunnel to the second tunnel endpoint. The second tunnel endpoint may receive the encapsulated packet. Cryptographic processing of the encapsulated packet may reveal the packet having a second header. The packet may then be forwarded on an interface toward at least one multicast recipient identified in the second header. | 11-26-2009 |
20100195529 | ENFORCING ACCESS CONTROL ON MULTICAST TRANSMISSIONS - Systems, apparatus, methods, and computer program products for multicast access control are provided to analyze incoming data based on a source zone and a destination zone of the incoming data. Appropriate access control rules are applied to incoming data based on the results of the analysis. Additional implementations of a multicast access control include using a proxy rendezvous point operable to function as a rendezvous point in place of a physical rendezvous point. | 08-05-2010 |
20120144191 | SECURE TRANSPORT OF MULTICAST TRAFFIC - A request to receive multicast data, associated with a multicast group, may be transmitted. The request may be transmitted via a tunnel. Group keys may be received in response to the request. The group keys may be based on the multicast group. An encapsulated packet may be received via another tunnel. The encapsulated packet may be processed, using the group keys, to obtain a multicast packet associated with the multicast data. The multicast packet may be forwarded to at least one multicast recipient. | 06-07-2012 |
Patent application number | Description | Published |
20160077110 | Detection of Misfolded Amyloid Beta Protein - Methods and kits are provided for amplifying and detecting Aβ proteins from samples, for example, from patients having Alzheimer's Disease. For example, a method for determining a presence of a soluble, misfolded Aβ protein may include contacting the sample with a monomeric, folded Aβ protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded Aβ protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded Aβ protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded Aβ aggregate present; and determining the presence of the soluble, misfolded Aβ protein in the sample by detecting at least a portion of the amplified portion of misfolded Aβ protein. | 03-17-2016 |
20160077111 | Detection of Misfolded Alpha Synuclein Protein - Methods and kits are provided for amplifying and detecting αS proteins from samples, for example, from patients having Parkinson's Disease. For example, a method for determining a presence of a soluble, misfolded αS protein may include: contacting the sample with a monomeric, folded αS protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded αS protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded αS protein in the presence of the soluble, misfolded αS protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded αS aggregate present; and determining the presence of the soluble, misfolded αS protein in the sample by detecting at least a portion of the soluble, misfolded αS protein. | 03-17-2016 |
20160077112 | Detection of Misfolded Proteins - Methods and kits are provided for amplifying and detecting misfolded proteins from samples, for example, from patients having Alzheimer's Disease, Parkinson's Disease, and the like. For example, a method for determining a presence of soluble, misfolded protein in a sample may include contacting the sample with a monomeric, folded protein to form an incubation mixture; conducting an incubation cycle two or more times effective to form an amplified portion of misfolded protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded protein; physically disrupting the incubation mixture effective to break up at least a portion of any protein aggregate present; and determining the presence of the soluble, misfolded protein in the sample by detecting at least a portion of the soluble, misfolded protein. The monomeric, folded protein and the soluble, misfolded protein may exclude prion protein (PrP) and isoforms thereof. | 03-17-2016 |
Patent application number | Description | Published |
20110295149 | APPARATUS FOR SOLUBILIZING TISSUE - Tissue solubilizing apparatuses are provided. The apparatuses may be useful to solubilize tissue, including skin, mucosal membrane, and other tissue. The apparatuses may be further useful to preserve and recover analytes contained within the solubilized skin, mucosal membrane, and other tissue. | 12-01-2011 |
20120003159 | COMPOSITIONS AND METHODS FOR ENHANCING CONTRAST IN IMAGING - Examples of compositions of liposomes and methods of making the same containing high concentrations of contrast-enhancing agents for computed tomography are provided. Example compositions of such liposomes, when administered to a subject, provide for increased contrast of extended duration, as measured by computed tomography, in the bloodstream and other tissues of the subject. Also provided are example methods for making the liposomes stable, that is, resistant to leakage of the contrast-enhancing agents, including the extrusion of the liposomes at high pressures and at high flow rates per total pore area of the extrusion filters. | 01-05-2012 |
20120004592 | COMPOSITIONS FOR SOLUBILIZING TISSUE - Tissue solubilizing compositions are provided. The compositions comprise 3-(decyl dimethyl ammonio) propane sulfonate and polyethylene glycol dodecyl ether, such as tetraethylene glycol dodecyl ether. The compositions may be useful to solubilize tissue, including skin, mucosal membrane, and other tissue. The compositions may be further useful to preserve and recover analytes contained within the solubilized skin, mucosal membrane, and other tissue. | 01-05-2012 |
20120253238 | COMPOSITIONS FOR SOLUBILIZING CELLS AND/OR TISSUE - Solubilizing compositions are provided. The compositions comprise at least one zwitterionic surfactant and at least one nonionic surfactant. In one embodiment, the compositions may be useful for solubilizing and remodeling and/or removing tissue on or beneath a patient's skin, optionally in conjunction with the application of energy to a region of interest on the skin. In one embodiment, at least one analyte may be collected and analyzed from the solubilized tissue. | 10-04-2012 |
20130189187 | NANO-SCALE CONTRAST AGENTS AND METHODS OF USE - Compositions and methods are disclosed for evaluating a subject's vasculature integrity, for differentiating between a malignant lesion and a benign lesion, for evaluating the accessibility of a tumor to nano-sized therapeutics, for treating tumors, and for live or real time monitoring of a nano-probe's biodistribution. | 07-25-2013 |
20140107560 | Compositions for solubilizing cells and/or tissue - Solubilizing compositions are provided. The compositions comprise at least one zwitterionic surfactant and at least one nonionic surfactant. In one embodiment, the compositions may be useful for solubilizing and remodeling and/or removing tissue on or beneath a patient's skin, optionally in conjunction with the application of energy to a region of interest on the skin. In one embodiment at least one analyte may be collected and analyzed from the solubilized tissue. | 04-17-2014 |